CCCC

C4 Therapeutics, Inc.

CCCC · CIK 1662579 · Annual (10-K) · Last 6 years

Financial Trends

Revenue$36M
20202025
Net Income−$105M
20202025
Operating CF−$99M
20202025
Free Cash Flow−$99M
20202025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Revenue$0.0B$0.0B$0.0B$0.0B——
Cost of Revenue——————
Gross Profit——————
R&D Expense$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B
SG&A Expense——————
Operating Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B
Net Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B
EPS (Basic)$-1.27$-1.52$-2.67$-2.62$-1.82$-5.83
EPS (Diluted)$-1.27$-1.52$-2.67$-2.62——

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Total Assets$0.4B$0.3B$0.4B$0.4B$0.5B$0.4B
Current Assets$0.3B$0.3B$0.3B$0.3B$0.3B$0.4B
Cash & Equivalents$0.1B$0.1B$0.1B$0.0B$0.1B$0.2B
Total Liabilities$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.1B$0.0B
Stockholders' Equity$0.3B$0.2B$0.2B$0.3B$0.4B$0.3B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Operating Cash Flow$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B
Investing Cash Flow$-0.0B$-0.1B$0.2B$0.1B$-0.2B$-0.2B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.1B$0.0B$0.0B$0.0B$0.2B$0.3B
← Companies